Background The efficacy and safetyof long-acting injectable risperidone have not been comparedwiththose of an oral atypical antipsychotic. Aims To compare long-acting risperidone and oral olanzapine in 377 patientswith DSM^IV schizophrenia

Abstract

Declaration of interest N.K. has received support fromorbeen a consultant for AstraZeneca,BristolMeyers Squibb,Janssen Pharmaceutica,Eli Lilly, Sanofi-Synthelabo,Pfizer andWyeth. M.I.,A.K. and K.K. are employees of Johnson & Johnson. The efficacy and safety of long-acting injectable risperidone have been evaluated in several trials of patients with… (More)

Topics

9 Figures and Tables

Cite this paper

@inproceedings{Keks2007BackgroundTE, title={Background The efficacy and safetyof long-acting injectable risperidone have not been comparedwiththose of an oral atypical antipsychotic. Aims To compare long-acting risperidone and oral olanzapine in 377 patientswith DSM^IV schizophrenia}, author={Nicholas A Keks and Michael P Ingham}, year={2007} }